Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Alginate as a cytocompatible carrier for mechanically isolated stromal vascular fraction: an in vitro proof-of-concept study.

Reid G., Seitz AK., Vasella M., Hofmann L., Dranseike D., Watson JA.

Laboratory Study on Chronic Wound, published in Sci Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Sci Rep (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42034692
PMCID
PMC13280390
DOI
10.1038/s41598-026-50191-0

Abstract (original English)

Human adipose tissue-derived mechanically isolated stromal vascular fraction (mSVF) is a heterogeneous cell population containing mesenchymal stromal and progenitor cells known to have immense regenerative potential. Current research aims to enhance mSVF delivery by improving cell retention and survival, with hydrogels emerging as promising scaffolds. Among them, alginate stands out due to its biocompatibility, cost-effectiveness, and established use in wound healing and tissue engineering. In this study, mSVF was cultured in varying concentrations of alginate for 21 days and tested for hydrogel degradation, cell viability, as well as protein and growth factor release. Alginate encapsulated mSVF was co-cultured with human dermal fibroblasts and analyzed via immunohistochemical and immunofluorescence imaging. After 21 days, all hydrogel samples maintained their original size and shape regardless of alginate concentration. Cell viability and protein release were comparable to those of the positive control (mSVF only). In addition, the co-culture exhibited increased fibroblast viability as compared with negative controls as well as increased CD31 and CD73 expression. This in vitro proof-of-concept study demonstrates that alginate is a cytocompatible carrier for mSVF, maintaining cell survival and structural integrity over 21 days. Further in vivo validation is required before clin

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansAlginatesFibroblastsMesenchymal Stem CellsCell SurvivalCoculture TechniquesHydrogelsStromal Vascular FractionTissue EngineeringBiocompatible Materials

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research